Analyst Price Target is GBX 2,700
▲ +22.63% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Craneware in the last 3 months. The average price target is GBX 2,700, with a high forecast of GBX 2,700 and a low forecast of GBX 2,700. The average price target represents a 22.63% upside from the last price of GBX 2,201.69.
Current Consensus is
Buy
The current consensus among 2 contributing investment analysts is to buy stock in Craneware. This Buy consensus rating has held steady for over two years.
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors. It also offers Trisus Decision Support; Trisus Labor Productivity; Trisus Medication Analytic solutions; and Trisus supplies assistant solutions. In addition, the company provides Sentinel, a drug tracking solution; Sentrex, a SaaS-based solution that helps covered entities expand medication access; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, it offers appeal, professional, and pharmacy professional services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
Read More